Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.